Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.
Here are five companies looking at possible drug approvals in January 2018.
Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.
The U.S. FDA approved Symproic (naldemedine) 0.2 mg tablets C-II for treating opioid-induced constipation in adult patients with chronic non-cancer pain.
Synergy Pharmaceuticals’ experimental once-daily tablet plecanatide met the main goal of a late-stage study on irritable bowel syndrome patients with constipation.
OSAKA, Japan and FLORHAM PARK, N.J., Aug. 3, 2015 /PRNewswire/ — Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Naldemedine is an investigational, oral, peripherally acting mu-opioid receptor antagonist (PAMORA). […]